Based in New York City, Weill Cornell Medicine Enterprise Innovation engages and collaborates with Weill Cornell Medicine faculty and trainees while fostering alliances with leaders in the biomedical industry and business and investment community. Our focus is to translate the application of emerging science and new technologies into world-class medical breakthroughs.
Integrating Weill Cornell Medicine’s different teams and resources under a single, united organization, Enterprise Innovation encompasses the entire spectrum of an effective innovation ecosystem. We offer unique opportunities for faculty and trainees to transform their research into medical advances through collaborations including access to the Tri-Institutional Therapeutics Discovery Institute.
Enterprise Innovation brings together the power of industry-leading translational research and clinical care combined with top-tier business development expertise to accelerate innovation to market. Our leading technology portfolio encompasses major pillars of biomedical innovation.
Weill Cornell Medicine has received a three-year, nearly $6 million grant to lead one of three national contraceptive research centers. The grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health, will fund the Weill Cornell Medicine Contraception Development Research Center. Led by Drs.
Dr. Hani Najafi, an assistant professor of cell and developmental biology, was the first WCM-Q participant in the $100K Biomedical Business Plan Challenge Pitch Day competition hosted by the BioVenture eLab. Enterprise Innovation asked him to share his latest study that can lead to potential therapies for cardiometabolic diseases and obesity.